CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 2020—Beckman Coulter’s Access PCT assay has received FDA 510(k) clearance and is available for sale in the United States. The assay enables health care providers to integrate procalcitonin testing analysis into their routine sepsis workups on core laboratory analyzers, as a primary or reflex test programmed through Beckman Coulter’s Remisol Advance middleware. Test results are available in less than 20 minutes.
Access PCT is available for use on the company’s Access family of immunoassay systems, including the Access 2, UniCel DxI 600, and UniCel DxI 800.
Pages: 1 2